The Proton Pump Inhibitor market is estimated to grow at a CAGR of 4.9% over the forecast period, from USD 2,750 million in 2021 to USD 3,585 million in 2027.
Proton pump inhibitors are a class of drugs that primarily reduce stomach acid production. Stomach acid is a chemical that aids digestion, but too much of it causes inflammation and irritation of the esophagus, resulting in heartburn, ulcers in the stomach, and the first section of the small intestine, all of which have an impact on market growth. It also helps with a variety of other stomach issues, particularly in cases like gastroesophageal reflux disease, in which stomach acid often leaks into the esophagus. When contrasted to H2 blockers, these Proton pump inhibitors are frequently used. These medications are available in the form of pills and capsules that the patient takes orally. Furthermore, this aids in the development of a microscopic clinical ailment known as colitis, which is fueling market expansion. Furthermore, by focusing on limiting acid secretion, the proton pump is directly responsible for the secretion of H+ ions into the stomach lumen, which is commonly seen in gastric acid secretion.
Increase in the incidence of gastrointestinal illnesses, increase in the elderly population suffering from stomach problems, increase in gastroesophageal reflux disease, increase in the consumption of unhealthy diets, expanding lifestyle linked with sedentary work culture, increased cases of obesity, and others are some of the primary factors positively affecting the market's growth throughout the forecast period. According to recent studies, the prevalence of GRED in North America is estimated to be 18.1%–27.8%, in Europe it is expected to be 8.8%–25.9%, in East Asia it is considered to be 2.5%–7.8%, in the Middle East it is projected to be 8.7%–33.1%, in Australia it is 11.6%, and in South America it is 23.0%.
10th Jul, 2020: Cadila Pharmaceuticals Ltd. Launches Esomeprazole tablets under brand name Esiloc™ in India for treatment of Hyperacidity --
Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of Esomeprazole tablets for treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc™. In an endeavor to improve the treatment options available for hyperacidity & drug induced Gastritis, Esiloc™ will be 50% more economical, thus making it a superior yet affordable choice. Esiloc™ will be made available in 20 mg and 40 mg tablets.
Esomeprazole is one of the most profitable pharmaceuticals on the market, and it is typically used to treat the symptoms of GERD, heartburn, and other problems involving excessive stomach acids. Until March 28, 2014, when the FDA approved it as an over-the-counter medicine, the substance was sold as a prescription drug. The transition from a prescription-only drug to an over-the-counter (OTC) drug is expected to be a primary driving force behind the drug's sales in the near future.
Market is segmented based on the type, applications, companies and regions.
By Type, it is segmented into
By Application, it is segmented into
North America is dominating the market owing to rise in GERD. Due to greater health awareness, increased per capita income expenditure, and improved healthcare infrastructure, Europe is the second-largest contributor to the market. The market in Asia Pacific is expected to develop significantly due to an increase in the elderly population, increased healthcare awareness, and increased government initiatives in the healthcare sector. Latin America and the Middle East are also expected to see significant market expansion.
The Proton Pump Inhibitor Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Proton Pump Inhibitor Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Report Attributes | Report Details |
Forecast Period 2022 to 2027 CAGR | CAGR of 4.9% over the forecast period (2022-2027) |
By Type |
|
By Application |
|
By Companies | AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly and Company, Eisai Inc., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Santarus Inc., Takeda Pharmaceuticals, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., Redhill Pharma Limited, Cipla Limited, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Janssen |
Regions Covered |
|
Countries Covered |
|
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2022 to 2027 |
Number of Pages | 108 |
Customization Available | Yes, the report can be customized as per your needs |
What is the growth rate of Proton Pump Inhibitor Market?
The Proton Pump Inhibitor Market is growing at a CAGR of 4.9% over the next 5 years.
Who are the key players in Proton Pump Inhibitor Market?
AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly and Company, Eisai Inc., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Santarus Inc., Takeda Pharmaceuticals, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., Redhill Pharma Limited, Cipla Limited, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Janssen
What are the significant types of Proton Pump Inhibitor Market?
Lansoprazole, Pantoprazole, Rabeprazole, Others
What are the major end-use applications of Proton Pump Inhibitor Market?
Hospital, Laboratory, Others
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.